X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca-mutated-metastatic-castration?utm_medium=email&utm_source=govdelivery#:~:text=On%20August%2011%2C%202023%2C%20the,as%20determined%20by%20an%20FDA%2D
https://www.ema.europa.eu/en/documents/overview/abiraterone-mylan-epar-medicine-overview_en.pdf
https://www.biospace.com/article/releases/health-canada-approves-lynparza-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer/
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration#:~:text=On%20May%2031%2C%202023%2C%20the,mCRPC)%2C%20as%20determined%20by%20an
https://www.business-standard.com/world-news/us-fda-panel-backs-restricted-use-of-astrazeneca-s-prostate-cancer-drug-123050100632_1.html
https://www.fiercepharma.com/pharma/astrazeneca-lynparza-combo-fda-advisory-committee-prostate-cancer-vote
https://endpts.com/janssen-gets-priority-review-for-prostate-cancer-combo-immunogen-reports-q1-elahere-sales/
https://www.europeanpharmaceuticalreview.com/news/180797/mhra-approves-prostate-cancer-combination-therapy/
https://www.astrazeneca.com/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer.html
https://www.globenewswire.com/news-release/2023/02/16/2609811/0/en/Janssen-Presents-Updated-Data-Demonstrating-Improved-Outcomes-from-the-Use-of-Niraparib-in-Combination-with-Abiraterone-Acetate-Plus-Prednisone-as-a-First-Line-Therapy-in-Patients-.html
https://www.prnewswire.com/news-releases/tavanta-therapeutics-announces-positive-top-line-results-from-pivotal-phase-3-trial-of-tavt-45-for-the-treatment-of-metastatic-prostate-cancer-301714563.html
https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-approved-in-the-eu-as-treatment-for-certain-patients-with-metastatic-castration-resistant-prostate-cancer/
https://www.fiercepharma.com/pharma/fda-needs-3-more-months-review-astrazeneca-and-mercks-lynparza-first-line-prostate-cancer
https://www.globenewswire.com/news-release/2022/09/10/2513543/0/en/POINT-Biopharma-Provides-Updated-Efficacy-and-Safety-Data-from-the-Lead-In-Cohort-of-the-Phase-3-SPLASH-Trial-in-mCRPC-at-ESMO-Congress-2022.html
https://www.thepharmaletter.com/article/lynparza-combo-accepted-by-fda-for-priority-review
https://www.europeanpharmaceuticalreview.com/news/172552/improved-outcome-for-prostate-cancer-patients-in-phase-iii-propel-trial/
https://endpts.com/astrazeneca-merck-come-out-of-asco-gu-with-a-big-win-over-jj-in-battle-over-prostate-cancer-franchises/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215947
https://www.clinicaltrialsarena.com/news/abiraterone-mortality-prostate-cancer/
https://www.targetedonc.com/view/overall-survival-in-high-risk-nonmetastatic-prostate-cancer-improved-with-abiraterone-acetate-and-prednisolone-based-treatment
https://www.icr.ac.uk/news-archive/abiraterone-keeps-men-with-prostate-cancer-at-risk-of-spreading-alive-for-longer
https://www.pharmacompass.com/pdf/news/mylans-abiraterone-mylan-abiraterone-acetate-receives-approval-in-europe-1632215271.pdf
https://medicaldialogues.in/news/industry/pharma/amneal-launches-abiraterone-acetate-tablets-post-usfda-nod-73344
https://www.icr.ac.uk/news-archive/icr-welcomes-nice-s-decision-to-reassess-abiraterone-as-first-line-treatment-for-advanced-prostate-cancer
https://www.esmo.org/meetings/esmo-virtual-congress-2020/daily-reporter/daily-reporter-news/profound-overall-survival-data-with-olaparib-herald-practice-changing-treatment-metastatic-prostate-cancer
https://www.fiercebiotech.com/biotech/esmo-roche-s-akt-inhibitor-scores-slight-win-over-j-j-s-zytiga
Market Place
Share 